Engineered high-purity clinical and commercial-grade peptides synthesized under stringent chromatographic controls.
Navigating the transition from recombinant biological fermentation to multi-ton synthetic peptide manufacturing.
Capitalizing on vertically integrated raw material synthesis, large-scale column chromatography, and technical precision.
Unlike Western contract manufacturers dependent on third-party suppliers for protected amino acids (Fmoc-Aib-OH, Fmoc-Lys(Alloc)-OH) and lipid mono/diacids (Octadecanedioic acid mono-tert-butyl ester), our Hangzhou manufacturing cluster executes upstream organic synthesis on-site. This eliminates raw material pinch points and ensures strict enantiomeric purity.
Equipped with 3000L to 10000L solid-phase peptide synthesis (SPPS) reactors and high-pressure industrial dynamic axial compression (DAC) chromatography systems up to 1000mm in diameter. Our synthesis base delivers steady multi-ton volume, reducing cycle times by 40% and cutting per-gram costs for global generic dossier applicants.
Extensive experience supporting IND, NDA, and ANDA submissions with the US FDA, EMA, and NMPA. We provide complete Chemistry, Manufacturing, and Controls (CMC) documentation packages, including validated RP-HPLC methods, HRMS structural confirmations, counter-ion control data (acetate/TFA), and ICH Q1A/B stability testing files.
Chemical synthesis allows total control over side reactions that confound recombinant fermentation routes.
| Critical Quality Attribute (CQA) | Commercial Target Specification | Analytical Methodology | Technical Significance for Drug Substance |
|---|---|---|---|
| HPLC Chromatographic Purity | ≥ 99.0% to ≥ 99.5% | Gradient RP-HPLC (C18 / C8) | Prevents therapeutic dosing drift and adverse immunogenic response. |
| Single Individual Impurity | ≤ 0.15% (or ≤ 0.10%) | UPLC-UV-QToF MS | Stringent control over truncated sequences [N-1, N+1] and D-enantiomers. |
| Mass Spectrometry Identity | Theoretical Molecular Mass ± 1.0 Da | High-Resolution ESI-MS / MALDI-TOF | Definitive molecular identification and verification of exact isotopic distribution. |
| Bacterial Endotoxin Levels | < 5.0 EU/mg (Custom < 1.0 EU/mg) | Kinetic Turbidimetric / Chromogenic LAL | Critical safety parameter for parenteral injectable formulations. |
| Counter-Ion Specification | Acetate (≤ 10.0%) or TFA (≤ 0.25%) | Ion-Exchange Chromatography (IC) | Complete conversion from trifluoroacetate avoids formulation instability. |
| Residual Solvents & Reagents | MeCN, DMF, DCM, Piperidine < ICH Limits | Headspace Gas Chromatography (GC-MS) | Ensures patient safety from processing reagent carryover. |
Strategic supply assurance addressing global incretin shortages and regional regulatory transitions.
With blockbuster GLP-1 drugs remaining on global drug shortage lists, generic manufacturers, 505(b)(2) developers, and compounding pharmacies face extreme supply volatility. Hangzhou Thinheal delivers commercial continuity via dedicated multi-hundred-kilogram capacity reservations, pre-validated DMF packages, and comprehensive analytical comparability data against reference listed drugs (RLDs).
Beyond commercial generic APIs, our contract development team collaborates with biotechs advancing proprietary multi-agonist therapies. We solve complex sequence synthesis issues—such as beta-hairpin stabilization, backbone N-methylation, head-to-tail cyclization, and site-selective fatty acid conjugation—providing an unbroken bridge from discovery to multi-ton commercialization.
Beyond mono GLP-1: The synthesis challenges of next-generation poly-agonists.
Lead Targets: Semaglutide, Liraglutide.
Mechanism: Satiety signaling, glucose-dependent insulin secretion, gastric deceleration.
Synthesis Focus: Controlled lipidation with C16/C18 diacids and removal of des-Gly deletion sequences.
Lead Targets: Tirzepatide, Mazdutide.
Mechanism: Enhanced insulinotropic synergy plus active white-adipose tissue lipolysis and energy expenditure.
Synthesis Focus: Management of sterically hindered residues and selective Lysine deprotection.
Lead Targets: Retatrutide, Cargrilintide combinations.
Mechanism: Broad-spectrum metabolic upregulation across pancreatic, hepatic, and hypothalamic tissues.
Synthesis Focus: Synthesis of 40+ amino acid chains requiring advanced fragment condensation.
Every gram is tested against rigorous purity, identity, and safety criteria to guarantee patient well-being.
Comprehensive identification of deletion peptides (N-1, N+1), insertion sequences, diastereomers (D-amino acid isomers), beta-aspartyl rearrangements, and methionine/tryptophan oxidation products via Orbitrap LC-HRMS.
Clear distinction between chromatographic purity and absolute peptide content. We provide quantitative Amino Acid Analysis (AAA) and elemental nitrogen testing to ensure precision in customer dosing calculations.
Complete ion-exchange capabilities to replace crude trifluoroacetic acid (TFA) salts with pharmaceutically preferred acetate, hydrochloride, or sodium forms, verified by ion chromatography with conductivity detection.
Lyophilized under ISO Class 5 cleanroom conditions. Materials undergo bioburden, total viable count, and kinetic turbidimetric endotoxin screening, packaged in amber borosilicate vials with monitored -20°C cold-chain logistics.
Clear answers on regulatory compliance, lead times, scale-up, and analytical validation.
Commercial-scale supply with full regulatory support and custom synthesis options.
Engage directly with our technical synthesis and regulatory specialists. Submit your target amino acid sequence, desired impurity limits, counter-ion profile, and annual procurement volume for a comprehensive commercial quotation.
Thin